A PET imaging approach for monitoring the therapeutically induced dynamic changes of active mutant EGFR kinase-expression in Preclinical and Clinical non-small cell lung carcinomas

Conclusions: 18F-MPG PET/CT imaging could accurately reflect the slight active mutant EGFR kinase-expression changes induced by EGFR-TKIsin a noninvasive way and real timeboth in preclinical and clinical. Cisplatin or Pemetrexed exposure resulted a dose-dependent decreasein active mutant EGFR NSCLCs, which this molecular level interfering on EGFR signal pathway can be also detected by 18F-MPGPET/CT imaging. Therefore,compared with 18F-FDG,18F-MPG PET/CT is a reliable tool in monitoring NSCLCs treatments, because of it is not easily affected by inflammation induced by chemotherapy and other factors. It has great potential in early treatment efficiency prediction, guiding follow-up treatment and evaluating prognosis in NSCLC therapy. References: [1] Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500 doi 10.1126/science.1099314. [2] Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England journal of medicine 2009;361(10):947-57 doi 10.1056/NEJMoa0810699. [3] Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, et al.A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Science Translational Medicine 2018;10(431) doi 10.1126/scitranslmed.aan8840.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Translational Image Guided Source Type: research

Related Links:

Cancers, Vol. 11, Pages 1411: Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC Cancers doi: 10.3390/cancers11101411 Authors: Julien Ancel Philippe Birembaut Maxime Dewolf Anne Durlach Béatrice Nawrocki-Raby Véronique Dalstein Gonzague Delepine Silvia Blacher Gaëtan Deslée Christine Gilles Myriam Polette In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractObjectivesThe aim of this study is to evaluate the surgical results of clinical N1 disease and to clarify the high-risk clinical N1 subgroup.MethodsBetween 1990 and 2012, 137 patients who were clinically diagnosed as having N1 disease were enrolled. Their medical records were reviewed to assess clinical characteristics, radiologic findings, pathologic results, postoperative outcomes, recurrence patterns, and survival. Logistic regression analysis was used to identify independent predictive factors for pathologic N2 upstaging. To determine which factors were significantly associated with survival, a multivariate ana...
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Authors: Yang M, Chen H, Zhou L, Chen K, Su F Abstract Non-small cell lung cancer (NSCLC) is a highly malignant type of cancer with a poor 5-year survival rate. The development of prognostic biomarkers and novel drug targets are required in order to improve the survival for NSCLC patients. Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors known to play key roles in many cellular biological processes. However, the roles of STAT family members in the development and progression of NSCLC have not yet been apparently determined. Our study investigated the roles of ST...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
OTUD7B, a multifunctional deubiquitinylase, plays an essential role in inflammation and proliferation signals. However, its function in lung cancer remains largely unknown. The aim of this study was to evaluate the prognostic significance of OTUD7B in patients with lung adenocarcinoma and squamous carcinoma and to characterize its molecular mechanisms in lung cancer progression and metastasis. Two tissue microarrays containing 150 pairs of lung squamous carcinoma and matched adjacent non-cancer tissues, and one tissue microarray containing 75 pairs of lung adenocarcinoma and adjacent non-cancer tissues were included, and i...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS SUMO1P3 expression was an independent indicator of reduced RFS in patients with LUAD. PMID: 31489957 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
ConclusionsThese findings support the use of immunohistological subtyping of NSCLC biopsy specimens to select patient-appropriate treatments.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Weekly vinorelbine monotherapy may be a feasible therapeutic option for patients with heavily treated, advanced NSCLC, particularly lung adenocarcinoma. PMID: 31480050 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Abstract Myoferlin, a protein of the ferlin family, has seven C2 domains and exhibits activity in some cells, including myoblasts and endothelial cells. Recently, myoferlin was identified as a promising target and biomarker in non-small-cell lung cancer, breast cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colon cancer, melanoma, oropharyngeal squamous cell carcinoma, head and neck squamous cell carcinoma, clear cell renal cell carcinoma and endometrioid carcinoma. This evidence indicated that myoferlin was involved in the proliferation, invasion and migration of tumour cells, the mechanism of which...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
Lung cancer is the leading cause of cancer deaths; its incidence and mortality is increasing rapidly. Non-small-lung-cancer (NSCLC) accounts for about 85% of all lung carcinomas, and the five-year survival rate is extremely low [1]. With the rapid development of molecular targeted therapy, anaplastic lymphoma kinase (ALK) was proven to be another main oncogene-driven gene after the epidermal growth factor receptor (EGFR). ALK fusions account for approximately 2% –7% of patients with lung adenocarcinoma [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
chezy M Abstract BACKGROUND: The cell adhesion molecule close homologue of L1 (CHL1) is a potential tumour suppressor and was recently detected in non-small cell lung cancer (NSCLC) specimens. The expression pattern, prognostic, and functional role of CHL1 in NSCLCs is unknown. METHODS: We evaluated the protein expression of CHL1 by immunohistochemistry in 2161 NSCLC patients based on a tissue microarray. The results were correlated with clinical, histopathological, and patient survival data (Chi square test, t test, and log-rank test, respectively). A multivariate analysis (Cox regression) was performed to v...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
More News: Adenocarcinoma | Alimta | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | CT Scan | Laboratory Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Nuclear Medicine | PET Scan | Science | Statistics | Study